TOXOPLASMOSIS TREATMENT DRUGS MARKET ANALYSIS

Toxoplasmosis Treatment Drugs Market by Drug Class (Pyrimethamine, Spiramycin, Leucovorin, Sulfadiazine, Folic Acid, and Others), by Indication (Chronic Toxoplasmosis Infection and Acute Toxoplasmosis Infection), by Route of Administration (Parenteral and Oral), by Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Jul 2023
Code : CMI4166
Pages :250
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Toxoplasmosis Treatment Drugs Market: Key Developments

On October 26, 2021, National Institute of Allergy and Infectious Diseases (NIAID) announced Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected patients. Patients take pyrimethamine or placebo three times a week. Patients also take leucovorin calcium orally three times weekly. Enrollment occurs over approximately 12 months. All patients are followed on study until a common study close-out date and final analysis of the study. It is anticipated that this common close-out will occur when the mean duration of time on study therapy will be 3 years. Patients receive a loading dose of pyrimethamine or placebo, plus of leucovorin calcium which was effective treatment for toxoplasmosis.

On March 20, 2020, Dr. Reddy’s Laboratories Ltd, a pharmaceutical company announced the launch of Pyrimethamine Tablets USP, 25 mg, a therapeutic equivalent and first-wave generic version of Daraprim (pyrimethamine) Tablets, approved by the U.S. Food and Drug Administration (FDA). This product is the only AB-rated generic version Daraprim (pyrimethamine) tablets approved by the U.S. FDA. Pyrimethamine is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination.